

**Perrigo Announces Leadership Change in Rx Pharmaceuticals Segment
Appoints John Wesolowski as Acting General Manager, Rx Pharmaceuticals**

DUBLIN, July 20, 2016 /PRNewswire/ -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a leading global provider of *Quality Affordable Healthcare Products*[®], today announced the departure of Douglas Boothe, Executive Vice President and General Manager, Rx Pharmaceuticals. John Wesolowski, Senior Vice President of Rx Commercial Operations, will assume the role of Acting General Manager, Rx Pharmaceuticals.

Perrigo's Chief Executive Officer John T. Hendrickson said, "John Wesolowski has the full confidence of our executive team to advance the business. He has 24 years of generic and specialty pharma experience and brings strong customer relationships, a deep understanding of our industry, and steady commercial leadership. We are conducting a thorough search process for a business leader who will focus on performance across our Rx portfolio and invest for future long-term growth. We are examining our overall Rx strategy and will continue to drive this organization to execute in the best interests of our shareholders."

As Senior Vice President of Rx Commercial Operations, Mr. Wesolowski oversees Rx sales, marketing, contracts, and customer service. In addition to these responsibilities, his role will now also include oversight of Rx finance and business development. Prior to joining Perrigo as Vice President of Commercial Operations in February 2004, Mr. Wesolowski served in several customer-facing roles at E. Fougera and Company from 1993 to 2004.

Mr. Hendrickson concluded, "We thank Doug for his contributions and wish him well in his future endeavors."

About Perrigo

Perrigo Company plc, a top five global over-the-counter ("OTC") consumer goods and pharmaceutical company, offers patients and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri[®]. Perrigo provides Quality Affordable Healthcare Products[®] across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other markets, including Israel, China and Latin America. Visit Perrigo online at (<http://www.perrigo.com>).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology

such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including the timing, amount and cost of share repurchases, future impairment charges, our ability to achieve our guidance and the ability to execute and achieve the desired benefits of announced initiatives. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-KT for the six-month period ended December 31, 2015, and form 10-Q for the quarter ended April 2, 2016 as well as the Company's subsequent filings with the SEC, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Logo - <http://photos.prnewswire.com/prnh/20120301/DE62255LOGO>

SOURCE Perrigo Company plc

For further information: Perrigo Contacts: Bradley Joseph, Vice President, Global Investor Relations, (269) 686-3373, bradley.joseph@perrigo.com, or Arthur J. Shannon, Vice President, Global Corporate Affairs and European Investor Relations, (269) 686-1709, ajshannon@perrigo.com

<https://investor.perrigo.com/2016-07-20-Perrigo-Announces-Leadership-Change-in-Rx-Pharmaceuticals-Segment>